Showing 26,101 - 26,120 results of 43,691 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((teer decrease) OR (mean decrease)) ))', query time: 1.14s Refine Results
  1. 26101

    <i>vang-1</i> shows reproduction- and aging-related defects. by Sebastian J. Honnen (183696)

    Published 2012
    “…<b>(B–C) </b><b><i>ok1142</i></b><b> and </b><b><i>tm1422</i></b><b> show decreased lipofuscin accumulation five and ten days after hatching.…”
  2. 26102

    Myelomonocytic expansion in blood, bone marrow, and spleen of young TAK1<sup>ΔM</sup> mice. by Betty Lamothe (57187)

    Published 2013
    “…<p>(<b>A</b>) Increased neutrophils and monocytes in young TAK1<sup>ΔM</sup> mice. Mean (± SEM) peripheral white blood cell differential counts from 6- to 8-week-old female TAK1<sup>F/+</sup> (n = 7) and TAK1<sup>ΔM</sup> (n = 10) mice show dramatic increases in neutrophils (<i>P</i><0.0001) and monocytes (<i>P</i> = 0.0083) and decreases in lymphocytes (<i>P</i><0.0001). …”
  3. 26103

    Distribution of estimated parameters by the three approaches. by Alireza Ghadimi (13839874)

    Published 2022
    “…The dual optimization approach improved the estimation precision by decreasing the standard deviation of the PDF and moving the mean of the PDFs closer to the true values. …”
  4. 26104

    DataSheet1_Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder.docx by Chaoli Chen (20359785)

    Published 2024
    “…Background<p>In the treatment of depression, medication plays a crucial role. However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression, and consequently imposing a greater economic burden on the healthcare system.…”
  5. 26105

    Morphine withdrawal-induced CREB activation in the PVN is dependent on α<sub>1</sub>-adrenoceptor stimulation. by Fátima Martín (333149)

    Published 2013
    “…Data correspond to mean ± SEM. Post hoc analysis revealed a significant decrease in pCREB immunoreactivity in prazosin-pretreated rats. …”
  6. 26106

    Characterization of phenotypically unique accessions. by Maria Stefania Przybylska (22756354)

    Published 2025
    “…The map was created with data from Natural Earth via the R package <i><i>rnaturalearth</i></i> [<a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003536#pbio.3003536.ref030" target="_blank">30</a>] (basemap shapefile: <a href="https://www.naturalearthdata.com/downloads/50m-cultural-vectors/" target="_blank">https://www.naturalearthdata.com/downloads/50m-cultural-vectors/</a>). …”
  7. 26107

    Increased Uptake of CHF5633 by Alveolar Monocyte. by Atsuyasu Sato (315849)

    Published 2013
    “…SP-C in CHF5633 input sample was given a value of 1. SP-C relative to Sat PC was decreased in supernatant or smaller form surfactant to half of that in input sample and BALF pellet samples. …”
  8. 26108

    Coarse-grained model leads to collective behavior. by Giovanna De Palo (476510)

    Published 2017
    “…The peak in susceptibility becomes higher the larger the number of cells, and NN distances decrease accordingly. Profiles in the inset were smoothed with a moving average filter spanning ten points. …”
  9. 26109
  10. 26110
  11. 26111
  12. 26112
  13. 26113
  14. 26114
  15. 26115
  16. 26116
  17. 26117
  18. 26118
  19. 26119

    Data_Sheet_1_SWL-1 Reverses Fluconazole Resistance in Candida albicans by Regulating the Glycolytic Pathway.doc by Xiao-Ning Li (2008540)

    Published 2020
    “…In this study, we show that SWL-1 reverses resistance to fluconazole in C. albicans when delivered in combination, with a sharp decrease in the IC<sub>50</sub> of fluconazole from >200 to 3.74 ± 0.25 μg/ml, and also reverses the fluconazole resistance of C. albicans in vitro, with IC<sub>50</sub> from >200 to 5.3 ± 0.3 μg/ml. …”
  20. 26120

    An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers by Moran Elishmereni (203218)

    Published 2011
    “…Simulations of the verified model surfaced important therapeutic insights: (1) Fractionating the standard daily regimen (50 µg/dose) into a twice daily schedule (25 µg/dose) is advantageous, yielding a significantly lower tumor mass (45% decrease); (2) A low-dose (12 µg/day) regimen exerts a response similar to that obtained under the 50 µg/day treatment, suggestive of an equally efficacious dose with potentially reduced toxicity. …”